araag2/HINT huggingface dataset:
Clinical trial NCT03406377 (phase 2, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: opk-88003, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Men or women aged 18 to 80 years with T2DM treated with diet and exercise alone or on
             a stable dose of metformin (≥ 1000 mg/day),

          -  BMI ≥27 and ≤45 kg/m2

          -  HbA1c ≥7.0% and ≤10.5% at screening

        Exclusion Criteria:

          -  Type 1 diabetes mellitus

          -  Previous treatment with incretin mimetic drugs

          -  Have used insulin for diabetic control for more than 6 consecutive days within the
             prior year

          -  Have had two or more emergency room visits or hospitalizations due to poor glucose
             control within the prior 6 months

          -  Have a history of acute or chronic pancreatitis or elevation in serum lipase/amylase
             (>2 x ULN).
Clinical trial NCT03421197 (phase 2, status: completed)
Conditions: psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: ppc-06 400 mg qd, ppc-06 400 mg bid, ppc-06 600 mg, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Generally healthy males or non-pregnant females age ≥18 years at the time of screening
             (or who have reached the state minimum legal age of consent).

          -  Stable, moderate-to-severe plaque psoriasis diagnosed for at least 6 months prior to
             randomization (no morphology changes or significant flares of disease activity in the
             last 6 months in the opinion of the investigator or as reported by the subject).

          -  Severity of disease meeting all 3 of the following criteria prior to randomization (at
             the Baseline [Day 0] visit):

               1. PASI score of ≥12

               2. Total body surface area (BSA) affected by plaque psoriasis of ≥10%

               3. IGA score of >3

          -  Must be a candidate for phototherapy and/or systemic therapy for psoriasis.

        Exclusion Criteria:

          -  Subjects with non-plaque psoriasis (ie, predominantly inverse, erythrodermic,
             predominantly guttate, or pustular psoriasis).

          -  Subjects with drug-induced psoriasis or subjects with drug-exacerbated psoriasis that
             has not resolved within 4 weeks prior to screening.

          -  Subjects who have received systemic non-biologic psoriasis therapy or phototherapy
             (including either oral and topical psoralen and ultraviolet A (PUVA) light therapy,
             ultraviolet B, or self-treatment with tanning beds or therapeutic sunbathing) within 4
             weeks prior to the Baseline Visit.

          -  Subjects who had topical psoriasis treatment within the previous 2 weeks prior to the
             Baseline Visit.

          -  Subjects with history of concurrent or recent use of any biologic agent within the
             following washout periods prior to baseline visit:

               -  Etanercept - 35 days

               -  Infliximab, adalimumab - 12 weeks

               -  Ustekinumab - 24 weeks

               -  Any other biologic agent <5 half-lives prior to the Baseline Visit

          -  Subjects with history of use of any investigational drug within 28 days prior to
             randomization, or 5 pharmacokinetic/ pharmacodynamic half-lives (whichever is longer).
Clinical trial NCT03424759 (phase 2, status: unknown status)
Conditions: non small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: azd9291
SMILES: COC1=C(NC2=NC=CC(=N2)C2=CN(C)C3=C2C=CC=C3)C=C(NC(=O)C=C)C(=C1)N(C)CCN(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed metastatic or recurrent stage IV NSCLC with activating EGFR
             mutation other than deletion in exon 19, L858R, T790M and insertion in exon 20

          -  metastatic or recurrent NSCLC

          -  Be 19years of age on day of signing informed consent

          -  ECOG performance status of 0 to 2

          -  At least one measurable lesion by RECIST 1.1(The part of radiation treatment in the
             palliative setting is excluded.)

          -  Untreated asymptomatic brain metastasis or symptomatic brain metastasis treated with
             local treatment such as operation, whole brain radiotherapy, or gamma-knife surgery

          -  At least 2 weeks later after whole brain radiotherapy or at least 4 weeks later after
             palliative thoracic radiotherapy

          -  Adequate organ function as evidenced by the following; Absolute neutrophil count > 1.5
             x 109/L; Hb > 9.0g/dL; platelets > 100 x 109/L; total bilirubin ≤1.5 UNL; AST and/or
             ALT < 2.5 ULN if no demonstrable liver metastases or < 5 UNL in the presence of liver
             metastases, CCr ≥ 50mL/min

          -  Written informed consent form

        Exclusion Criteria:

          -  Prior treatment with EGFR TKI

          -  Major surgery undertaken less than 4 weeks before the study

          -  Localized palliative radiotherapy unless completed more than 2 weeks before the study

          -  Uncontrolled systemic illness such as DM, CHF, unstable angina, hypertension or
             arrhythmia

          -  Pregnant or nursing women (Women of reproductive potential have to agree to use an
             adequate contraceptive method)

          -  Uncontrolled symptomatic brain metastasis

          -  Prior history of malignancy within 5 years from study entry except for adequately
             treated basal cell or squamous cell skin cancer or in situ cervical cancer, or
             well-treated thyroid cancer

          -  Concomitant use of CYP3A4 inducers/inhibitors

          -  Prolonged QT interval in ECG (QTc >450 msec)

          -  Prior history of interstitial lung disease
Clinical trial NCT03427229 (phase 2, status: completed)
Conditions: clostridium difficile, pseudomembranous colitis
ICD codes: A04.71, A04.72
Drugs: vancomycin (before randomization)
SMILES: CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]4C[C@](C)(N)[C@H](O)[C@H](C)O4)C4=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]1C3=CC(=C(O)C=C3)C3=C(O)C=C(O)C=C3[C@H](NC(=O)[C@@H](NC1=O)[C@H](O)C1=CC(Cl)=C(O4)C=C1)C(O)=O)C(Cl)=C2
Eligibility criteria:

        Inclusion criteria:

          -  Recurrent C. difficile infection (identified by positivity of C. difficile toxin in
             stools) with severe clinical picture (defined by the ESCMID Guidelines published in
             2014 - Debast et al, Clin Microbiol Infect 2014)

          -  Possibility to undergo standard antimicrobial therapy for recurrent C. difficile
             infection Approval of informed consent

          -  Possibility to undergo protocol diagnostic and therapeutic procedures

          -  Stool negativity for parasites

          -  Stool negativity for Salmonella spp., Shigella spp., Yersinia enterocolitica,
             Campylobacter, Streptococcus agalactiae, Staphylococcus aureus, enteropathogenic
             Escherichia coli and other microorganisms except for C. difficile

          -  Blood negativity for: Hepatitis A virus-Immunoglobulin M, HBsAg, Anti-Hepatitis C
             Virus, Anti-Human Immunodeficiency Virus1-2, venereal disease reaction level (VDRL).

        Exclusion Criteria:

          -  Subjects <18 years old

          -  Prior colectomy

          -  Negativity of C. difficile toxin in stools

          -  Mild clinical picture of C. difficile infection

          -  High risk of post-colonoscopy complications

          -  Other main gastrointestinal diseases (es. Crohn's disease or ulcerative colitis)

          -  Stool positivity for parasites

          -  Stool positivity for Salmonella spp., Shigella spp., Yersinia enterocolitica,
             Campylobacter, Streptococcus agalactiae, Staphylococcus aureus, enteropathogenic
             Escherichia coli and other microorganisms except for C. difficile

          -  Blood positivity for: Hepatitis A virus-Immunoglobulin M, HBsAg, Anti-Hepatitis C
             Virus, Anti-Human Immunodeficiency Virus1-2, venereal disease reaction level (VDRL).

          -  Pregnancy or breastfeeding.

          -  Inability to follow protocol procedures
Clinical trial NCT03439215 (phase 2, status: unknown status)
Conditions: carcinoma, non-small-cell lung
ICD codes: D02.20, D02.21, D02.22
Drugs: lorlatinib
SMILES: C[C@H]1OC2=C(N)N=CC(=C2)C2=C(C#N)N(C)N=C2CN(C)C(=O)C2=C1C=C(F)C=C2
Eligibility criteria:

        Inclusion Criteria:

          1. Written informed consent;

          2. Male or female patient ages ≥ 18 years;

          3. Histologically/cytologically confirmed diagnosis of NSCLC with evidence of ROS1
             rearrangement;

          4. Possibility to perform a new tumor biopsy or tumor tissue collected at the time or
             after crizotinib failure;

          5. Patient pretreated with crizotinib with evidence of disease progression during
             crizotinib therapy;

          6. At least one radiological measurable disease according to RECIST criteria;

          7. At least 1 previous standard chemotherapy regimen;

          8. Performance status 0-2 (ECOG);

          9. Patient compliance to trial procedures

         10. Adequate bone marrow function (ANC ≥ 1.5x109/L, platelets ≥ 100x109/L, haemoglobin > 9
             g/dl);

         11. Adequate liver function (bilirubin < grade 2, transaminases no more than 3xULN/<5xULN
             in present of liver metastases);

         12. Normal level of alkaline phosphatase and creatinine;

         13. If female: childbearing potential either terminated by surgery, radiation, or
             menopause, or attenuated by use of approved contraceptive method [intrauterine
             contraceptive device (IUD), birth control pills, or barrier device] during and for
             ninety (90) days after end of treatment.

        Exclusion Criteria:

        1. No ROS1 rearrangement 2. No previous therapy with crizotinib; 3. No evidence of
        crizotinib failure; 4. No post-crizotinib tumor tissue available; 5. Absence of any
        measurable lesions; 6. No previous chemotherapy; 7. Concomitant radiotherapy or
        chemotherapy; 8. Symptomatic brain metastases; 9. Diagnosis of any other malignancy during
        the last 5 years, except for in situ carcinoma of cervix uteri and squamous cell carcinoma
        of the skin; 10. Predisposing factors for acute pancreatitis (e.g., uncontrolled
        hyperglycaemia, current gallstone disease, alcoholism); 11. History of extensive
        disseminated/bilateral or known presence of Grade 3 or 4 interstitial fibrosis or
        interstitial lung disease including a history of pneumonitis, hypersensitivity pneumonitis,
        interstitial pneumonia, interstitial lung disease, obliterative bronchiolitis and pulmonary
        fibrosis (but not history of prior radiation pneumonitis); 12. Pregnancy or lactating
        female; 13. Other serious illness or medical condition potentially interfering with the
        study.

        -
Clinical trial NCT03443024 (phase 2, status: completed)
Conditions: atopic dermatitis
ICD codes: L20.89, L20.9
Drugs: placebos
SMILES: COCCC1=CC=C(OCC(O)CNC(C)C)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female, 18 years or older.

          -  Chronic AD as defined by Hanifin and Rajka (1980) that has been present for ≥1 year
             before the screening visit .

          -  Eczema Area and Severity Index (EASI) score ≥16 at the screening and the baseline
             visit.

          -  Investigator Global Assessment (IGA) score ≥3 (scale of 0 to 4) at the screening and
             the baseline visit.

          -  ≥10% body surface area (BSA) of AD involvement at the screening and the baseline
             visit.

        Exclusion Criteria:

          -  Treatment with any of the following agents within 4 weeks prior to the baseline visit:

          -  Immunosuppressive/immunomodulating drugs (e.g., systemic corticosteroids,
             cyclosporine, mycophenolate-mofetil, IFN-γ, Janus kinase inhibitors, azathioprine,
             methotrexate, etc.)

          -  Phototherapy and photochemotherapy (PUVA) for AD.

          -  Treatment with topical corticosteroids (TCS) or topical calcineurin inhibitors (TCI)
             within 1 week prior to the baseline visit.

          -  Treatment with:

          -  An investigational drug within 8 weeks or within 5 half-lives (if known), whichever is
             longer, prior to the baseline visit.

          -  Dupilumab within 3 months prior to baseline visit.

          -  Cell-depleting biologics, including rituximab, within 6 months prior to the baseline
             visit.

          -  Other biologics within 5 half-lives (if known) or 16 weeks prior to baseline visit
             (whichever is longer).

          -  Use of prescription moisturizers within 7 days of the baseline visit.
Clinical trial NCT03444506 (phase 2, status: completed)
Conditions: seasonal allergic rhinitis
ICD codes: J30.2
Drugs: molo 1 (also referred as gsp 301-2 ns), molo 2 (also referred as gsp 301-1 ns), placebo nasal spray, dymista nasal spray, patanase nasal spray
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female patients aged 18 to 65 years (inclusive) with a clinical history of
             seasonal allergic rhinitis (SAR) (for at least 2 years) and exhibiting a positive skin
             prick test

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Patients with known hypersensitivity to any of the components of the formulation

          -  Patients with a history of seasonal asthma during ragweed season.

          -  Patient requiring chronic use of inhaled or systemic corticosteroids

          -  Patients with perennial rhinitis; non-allergic rhinitis; or ocular infection within 3
             weeks before the screening

          -  Patients with history of acute or significant chronic sinusitis or chronic purulent
             post-nasal drip or Rhinitis Medicamentosa as determined by the Investigator.

          -  Patients with history of narrow-angle glaucoma, increased intraocular pressure,
             posterior subcapsular cataract, urinary retention, uncontrolled hypertension, severe
             Coronary Artery Disease, Ischemic Heart Disease, uncontrolled Diabetes Mellitus,
             Hyperthyroidism, Renal Impairment or Prostatic Hypertrophy, and those receiving MAO
             inhibitor therapy.
Clinical trial NCT03446144 (phase 2, status: withdrawn)
Conditions: geographic atrophy, age related macular degeneration
ICD codes: K14.1, H35.3130, H35.3230, H35.3110, H35.3120, H35.3131, H35.3132, H35.3190
Drugs: ionis-fb-lrx, placebo (sterline saline 0.9%)
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    business objective change, no safety or efficacy concerns
  
Eligibility criteria:

        Key Inclusion Criteria:

          1. Must have given written informed consent and be able to comply with study requirements

          2. Females must be non-pregnant and non-lactating, and either surgically sterile or
             post-menopausal. Males must be surgically sterile or, if engaged in sexual relations
             with a female of child bearing potential, the subject must be using an acceptable
             contraceptive method from the time of signing the informed consent form until at least
             a period of 13 weeks after the last dose of Study Drug (ISIS 696844 or placebo)

          3. Well-demarcated Geographic Atrophy due to Age Related Macular Degeneration

        Key Exclusion Criteria:

          1. Clinically-significant abnormalities in medical history

          2. Diagnosis of primary or secondary immunodeficiencies of B lymphocyte function,
             splenectomy, glomerulonephritis or history of recurrent meningococcal disease

          3. Diabetes mellitus or thyroid disease unless well controlled for a period of at least 3
             months

          4. Clinically-significant abnormalities in screening laboratory values

          5. Unwillingness to be administered, or history of a serious reaction to protocol
             required vaccines

          6. Known history of or positive test for human immunodeficiency virus (HIV), hepatitis C
             or chronic hepatitis B

          7. History or presence of a disease other than AMD in study eye
Clinical trial NCT03449199 (phase 2, status: completed)
Conditions: diabetic kidney disease
ICD codes: E10.22, E11.22, E13.22, E08.22, E09.22
Drugs: tmx-049, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetes treated with ≥1 glucose-lowering medication for at least 12 months

          -  UACR 200 to 3000 mg/g

          -  eGFR ≥30 ml/min/1.73m2

          -  Treated with at least the minimal recommended dose of an angiotensin converting enzyme
             inhibitor (ACEI) or an angiotensin II receptor blocker (ARB), but not both

        Exclusion Criteria:

          -  History of Type 1 diabetes

          -  Women who are breast feeding

          -  Treatment with any uric acid-lowering therapy within previous 2 weeks

          -  History of intolerance to any XO inhibitor

          -  History of a gout flare requiring pharmacologic treatment

          -  History or presence of tophaceous gout

          -  History of immunosuppressant treatment for any known or suspected renal disorder

          -  History of a non-diabetic form of renal disease

          -  Glycosylated hemoglobin (HbA1c) >11%

          -  sUA <4.0 mg/dL or >10.0 mg/dL

          -  Positive urinary pregnancy test

          -  Dialysis for acute renal failure within previous 6 months

          -  Renal allograft in place or a scheduled kidney transplant within the next 22 weeks

          -  Congenital or acquired solitary kidney
Clinical trial NCT03460756 (phase 2, status: completed)
Conditions: depressive disorder, depression, depression, postpartum, behavioral symptoms, mood disorders, mental disorder, pregnancy complications, postpartum blues, ppd, postpartum disorder
ICD codes: F25.1, F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F32.A, F53.0, P91.4, Z13.31, Z13.32, F53.0, F34.81, F39, F34.9, F43.21, F10.14, F10.24, F11.14, F48.9, F99, F51.05, F51.13, F09, F06.8, F48.8, O04.80, O04.89, O22.8X1, O22.8X2, O22.8X3, O22.8X9, O04.85
Drugs: ganaxolone, placebo
SMILES: [H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@](C)(O)CC[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Experiencing a major depressive episode, which started between the start of the third
             trimester and 4 weeks following delivery. The major depressive episode must be
             diagnosed according to Mini International Neuropsychiatric Interview (MINI) 7.0
             interview

          -  Given birth in the last 6 months

          -  HAMD17 score of ≥ 20 at screening but < 26

          -  Must agree to stop breastfeeding from start of study treatment or must agree to
             temporarily cease giving breast milk to her infant(s)

        Exclusion Criteria:

          -  Current history of any psychotic illness, including major depressive episode with
             psychotic features

          -  History of suicide attempt within the past 3 years

          -  History of bipolar I disorder

          -  History of seizure discorder
Clinical trial NCT03469934 (phase 2, status: completed)
Conditions: eosinophilic asthma
ICD codes: J82.83
Drugs: anb020, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female patients aged ≥18 to ≤65 years and able to give informed consent.

          -  Patients with a confirmed clinical diagnosis of eosinophilic asthma

          -  History of diagnosis of eosinophilic asthma

          -  Severe asthma diagnosed according to the Global Initiative for Asthma (GINA) 2016

          -  Body mass index (BMI) of 18 to 38 kg/m2 (inclusive) and total body weight >50 kg (110
             lb.).

          -  Women of childbearing potential must have a negative serum pregnancy test at screening
             and be willing to use effective methods of contraception throughout the study.

          -  Male patients must be willing to use effective methods of contraception during the
             entire study period.

          -  Patient must be on high dose ICS plus LABA.

          -  Willing and able to comply with the study protocol requirements.

          -  Have the ability to read and understand the study procedures and can communicate
             meaningfully with the Investigator and staff.

        Exclusion Criteria:

          -  Have concomitant medical condition(s) which may interfere with the Investigator's
             ability to evaluate the patient's response to the IP.

          -  Have experienced severe life threatening anaphylactic reactions.

          -  Have received any IP within a period of 3 months or 5 half lives of an IP

          -  Have received high dose systemic corticosteroids

          -  Have received treatment with biologics within 3 months or 5 half lives (whichever is
             longer) before screening.

          -  Abnormal ECG assessment at screening

          -  Uncontrolled hypertension, or acute ischemic cardiovascular diseases.

          -  If female, is pregnant or lactating, or intend to become pregnant during the study
             period.

          -  History (or suspected history) of alcohol or substance abuse within 2 years before
             screening.

          -  Any comorbidity that the Investigator believes is a contraindication to study
             participation.

          -  Have any other physical, mental, or medical conditions which, in the opinion of the
             Investigator, make study participation inadvisable or could confound study
             assessments.

          -  Planned surgery during the study or 30 days before screening.

          -  History of malignancy within 5 years, except non melanoma skin cancer which has been
             fully treated with no current active disease.
Clinical trial NCT03471767 (phase 2, status: completed)
Conditions: smoking cessation, smoking, cigarette, nicotine dependence
ICD codes: Y36.881S, Y36.891S, Y36.880S, Y36.881A, Y36.881D, Y36.890S, Y36.891A, F17.200, F17.210, F17.208, F17.209, F17.218, F17.219, F17.228
Drugs: axs-05, bupropion sr
SMILES: CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1, CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1
Eligibility criteria:

        Key Inclusion Criteria:

          1. Age 18 years or above

          2. Daily smoker using 10 or more cigarettes per day

          3. Willing to be smoke-free for 7 days

          4. Is able to provide written informed consent (in English) to participate in the study
             and able to understand the procedures and study requirements.

          5. Is willing to voluntarily sign and date an informed consent form that is approved by
             an institutional review board before the conduct of any study procedure.

        Key Exclusion Criteria:

          1. Current use of a smoking cessation medication (e.g. nicotine replacement, Varenicline,
             bupropion)

          2. Current use of tobacco product other than cigarettes (e.g. e-cigarettes, smokeless
             tobacco)

          3. Not pregnant or breastfeeding

          4. Contraindication to the use of bupropion.

          5. Additional criteria may apply.